Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study

Ophthalmology

Volumn 123, Issue 12, 2016, Pages 2545-2553

  Gillies, Mark C ^a   Nguyen, Vuong ^a   Daien, Vincent ^a,b,c   Arnold, Jennifer J ^d   Morlet, Nigel ^e   Barthelmes, Daniel ^a,f  

^a UNIVERSITY OF SYDNEY   (Australia)

^b GUI DE CHAULIAC HOSPITAL   (France)

^c INSERM U1061   (France)

^d Marsden Eye Specialists   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POST HOC ANALYSIS; PRIORITY JOURNAL; TREATMENT RESPONSE; VERY ELDERLY; VISUAL ACUITY; WET MACULAR DEGENERATION; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; REGISTER; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; DRUG SUBSTITUTION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; REGISTRIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84996559018     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2016.08.016     Document Type: Article

References (42)

1. 1 Schmidt-Erfurth, U., Chong, V., Loewenstein, A., et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 98 (2014), 1144–1167.
2. 2 American Academy of Ophthalmology Retina/Vitreous Panel. Preferred Practice Pattern® Guidelines. Age-Related Macular Degeneration. 2015, American Academy of Ophthalmology, San Francisco, CA.
3. 3 Brown, D.M., Kaiser, P.K., Michels, M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006), 1432–1444.
4. 4 Rosenfeld, P.J., Brown, D.M., Heier, J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006), 1419–1431.
5. 5 Busbee, B.G., Ho, A.C., Brown, D.M., et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 120 (2013), 1046–1056.
6. 6 Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin, D.F., Maguire, M.G., et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119 (2012), 1388–1398.
7. 7 Chin-Yee, D., Eck, T., Fowler, S., et al. A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol, 2015 pii: bjophthalmol-2015–306987 http://dx.doi.org/10.1136/bjophthalmol-2015-306987 [Epub ahead of print].
8. 8 Heimes, B., Lommatzsch, A., Zeimer, M., et al. Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme. Graefes Arch Clin Exp Ophthalmol 249 (2011), 639–644.
9. 9 Hjelmqvist, L., Lindberg, C., Kanulf, P., et al. One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicentre study. J Ophthalmol, 2011, 2011, 405724.
10. 10 Menghini, M., Kloeckener-Gruissem, B., Fleischhauer, J., et al. Impact of loading phase, initial response and CFH genotype on the long-term outcome of treatment for neovascular age-related macular degeneration. PLoS One, 7, 2012, e42014.
11. 11 Finger, R.P., Wiedemann, P., Blumhagen, F., et al. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol (Copenh) 91 (2013), 540–546.
12. 12 Cohen, S.Y., Mimoun, G., Oubraham, H., et al. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina 33 (2013), 474–481.
13. 13 Gillies, M.C., Walton, R., Simpson, J.M., et al. Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naive eyes. Invest Ophthalmol Vis Sci 54 (2013), 5754–5760.
14. 14 Gillies, M.C., Campain, A., Barthelmes, D., et al. Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study. Ophthalmology 122 (2015), 1837–1845.
15. 15 Holz, F.G., Tadayoni, R., Beatty, S., et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 99 (2015), 220–226.
16. 16 Frennesson, C.I., Nilsson, S.E.G., A three-year follow-up of ranibizumab treatment of exudative AMD: impact on the outcome of carrying forward the last acuity observation in drop-outs. Acta Ophthalmol (Copenh) 92 (2014), 216–220.
17. 17 Chavan, R., Panneerselvam, S., Adhana, P., et al. Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration. Clin Ophthalmol 8 (2014), 717–723.
18. 18 U.S. Food and Drug Administration. FDA news release (2011): FDA approves Eylea for eye disorder in older people. www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm280601.htm; Accessed December 16, 2013.
19. 19 Heier, J.S., Brown, D.M., Chong, V., et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119 (2012), 2537–2548.
20. 20 Schmidt-Erfurth, U., Kaiser, P.K., Korobelnik, J.-F., et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 121 (2014), 193–201.
21. 21 Singh, R.P., Srivastava, S.K., Ehlers, J.P., et al. A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis. Clin Ophthalmol 9 (2015), 1759–1766.
22. 22 Heussen, F.M., Shao, Q., Ouyang, Y., et al. Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 252 (2014), 909–915.
23. 23 Ho, V.Y., Yeh, S., Olsen, T.W., et al. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol 156 (2013), 23–28.e2.
24. 24 Kumar, N., Marsiglia, M., Mrejen, S., et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 33 (2013), 1605–1612.
25. 25 Chang, A.A., Broadhead, G.K., Hong, T., et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration: 12-month safety and efficacy outcomes. Ophthalmic Res 55 (2015), 84–90.
26. 26 Arcinue, C.A., Ma, F., Barteselli, G., et al. One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration. Am J Ophthalmol 159 (2015), 426–436.e2.
27. 27 Yonekawa, Y., Andreoli, C., Miller, J.B., et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol 156 (2013), 29–35.e2.
28. 28 Holash, J., Davis, S., Papadopoulos, N., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99 (2002), 11393–11398.
29. 29 Papadopoulos, N., Martin, J., Ruan, Q., et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15 (2012), 171–185.
30. 30 Yu, L., Liang, X.H., Ferrara, N., Comparing protein VEGF inhibitors: in vitro biological studies. Biochem Biophys Res Commun 408 (2011), 276–281.
31. 31 Yang, J., Wang, X., Fuh, G., et al. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A. Mol Pharm 11 (2014), 3421–3430.
32. 32 Gillies, M.C., Walton, R., Liong, J., et al. Efficient capture of high-quality data on outcomes of treatment for macular diseases: the fight retinal blindness! Project. Retina 34 (2014), 188–195.
33. 33 Stuart, E.A., Matching methods for causal inference: a review and a look forward. Stat Sci 25 (2010), 1–21.
34. 34 Unnebrink, K., Windeler, J., Intention-to-treat: methods for dealing with missing values in clinical trials of progressively deteriorating diseases. Stat Med 20 (2001), 3931–3946.
35. 35 Barthelmes, D., Walton, R., Campain, A.E., et al. Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data. Br J Ophthalmol 99 (2015), 359–364.
36. 36 Walters, S.J., Consultants’ forum: should post hoc sample size calculations be done?. Pharm Stat 8 (2009), 163–169.
37. 37 R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria, 2015 http://www.R-project.org/ Accessed August 12, 2016.
38. 38 Sarwar, S., Clearfield, E., Soliman, M.K., et al. Aflibercept for neovascular age-related macular degeneration. Cochrane Database Syst Rev, 2, 2016, CD011346.
39. 39 Souied, E.H., Oubraham, H., Mimoun, G., et al. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: The TWIN Study. Retina 35 (2015), 1743–1749.
40. 40 Gillies, M.C., Campain, A., Walton, R., et al. Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab. Ophthalmology 122 (2015), 589–594.e1.
41. 41 Barthelmes, D., Campain, A., Nguyen, P., et al. Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration. Br J Ophthalmol, 2016 pii: bjophthalmol-2015–308090 http://dx.doi.org/10.1136/bjophthalmol-2015-308090 [Epub ahead of print].
42. 42 Concato, J., Shah, N., Horwitz, R.I., Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 342 (2000), 1887–1892.